104 related articles for article (PubMed ID: 37846815)
1. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis.
Hu H; Li B; Chen H; Fan G; Ye Z; Ji S; Yu X; Xu X; Qin Y
Mol Carcinog; 2024 Feb; 63(2):195-208. PubMed ID: 37846815
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer.
Wang Z; Qin J; Zhao J; Li J; Li D; Popp M; Popp F; Alakus H; Kong B; Dong Q; Nelson PJ; Zhao Y; Bruns CJ
Theranostics; 2020; 10(16):7178-7192. PubMed ID: 32641986
[TBL] [Abstract][Full Text] [Related]
3. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.
Zhao Y; Altendorf-Hofmann A; Pozios I; Camaj P; Däberitz T; Wang X; Niess H; Seeliger H; Popp F; Betzler C; Settmacher U; Jauch KW; Bruns C; Knösel T
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1061-1068. PubMed ID: 28210844
[TBL] [Abstract][Full Text] [Related]
4. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
6. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
7. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Zhao T; Jin F; Xiao D; Wang H; Huang C; Wang X; Gao S; Liu J; Yang S; Hao J
Theranostics; 2020; 10(9):4088-4100. PubMed ID: 32226541
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
9. Glycolysis and tumor progression promoted by the m
Yang K; Zhong Z; Zou J; Liao JY; Chen S; Zhou S; Zhao Y; Li J; Yin D; Huang K; Li Y
Cancer Lett; 2024 May; 590():216840. PubMed ID: 38604311
[TBL] [Abstract][Full Text] [Related]
10. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
11. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
[TBL] [Abstract][Full Text] [Related]
12. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract][Full Text] [Related]
13. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
14. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-448 suppresses metastasis of pancreatic ductal adenocarcinoma through targeting JAK1/STAT3 pathway.
Yu DL; Zhang T; Wu K; Li Y; Wang J; Chen J; Li XQ; Peng XG; Wang JN; Tan LG
Oncol Rep; 2017 Aug; 38(2):1075-1082. PubMed ID: 28677798
[TBL] [Abstract][Full Text] [Related]
16. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.
Lin C; Li T; Wang Y; Lai S; Huang Y; Guo Z; Zhang X; Weng S
Cell Death Dis; 2023 Mar; 14(3):221. PubMed ID: 36977668
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
18. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
19. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
20. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity.
Ruan Q; Wen C; Jin G; Yuan Z; Yang X; Wen Z; Huang G; Li G; Deng J; Bai Y
Phytomedicine; 2023 Sep; 118():154990. PubMed ID: 37494874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
